Preclinical development of SIG-007 for treatment of Fabry disease

被引：0
作者：
Fluharty, Brian [1 ]
Makino, Elina [1 ]
Donovan, Marissa [1 ]
Tietz, Drew [1 ]
Pearson, Erika [1 ]
Jansen, Lauren [1 ]
Barney, Lauren [1 ]
Sewell, Jared [1 ]
Huang, Janet [1 ]
Corzo, Deya [1 ]
Moller, David [1 ]
Peritt, David [1 ]
Vivaldi, Rogerio [1 ]
机构：
[1] Sigilon Therapeut, Cambridge, MA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2020年 / 129卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2019.11.130
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
121
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [31] Therapeutic goals in the treatment of Fabry disease
    Mehta, Atul
    West, Michael L.
    Pintos-Morell, Guillem
    Reisin, Ricardo
    Nicholls, Kathy
    Figuera, Luis E.
    Parini, Rossella
    Carvalho, Luiz R.
    Kampmann, Christoph
    Pastores, Gregory M.
    Lidove, Olivier
    GENETICS IN MEDICINE, 2010, 12 (11) : 713 - 720
  • [32] PSYCHOSIS IN FABRY DISEASE AND TREATMENT WITH PHENOXYBENZAMINE
    LISTON, EH
    LEVINE, MD
    PHILIPPART, M
    ARCHIVES OF GENERAL PSYCHIATRY, 1973, 29 (03) : 402 - 403
  • [33] Progress in the understanding and treatment of Fabry disease
    Miller, James J.
    Kanack, Adam J.
    Dahms, Nancy M.
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2020, 1864 (01):
  • [34] Treatment of Anderson-Fabry disease
    Linhart, Ales
    HEART, 2008, 94 (02) : 138 - 139
  • [35] Preclinical anti-inflammatory activity of SIG1311, a candidate for the topical treatment of atopic dermatitis
    Fernandez, J. R.
    Perez, E.
    Voronkov, M.
    Rouzard, K.
    Stock, M.
    Gordon, J. S.
    Shroot, B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 : S2 - S2
  • [36] Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs Questionnaire
    Esther Noël
    Bertrand Dussol
    Didier Lacombe
    Najya Bedreddine
    Alain Fouilhoux
    Pierre Ronco
    Delphine Genevaz
    Soumeya Bekri
    Albert Hagège
    Frédérique Dupuis-Siméon
    Valérie Derrien Ansquer
    Dominique P. Germain
    Olivier Lidove
    Orphanet Journal of Rare Diseases, 14
  • [37] Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs Questionnaire
    Noel, Esther
    Dussol, Bertrand
    Lacombe, Didier
    Bedreddine, Najya
    Fouilhoux, Alain
    Ronco, Pierre
    Genevaz, Delphine
    Bekri, Soumeya
    Hagege, Albert
    Dupuis-Simeon, Frederique
    Ansquer, Valerie Derrien
    Germain, Dominique P.
    Lidove, Olivier
    ORPHANET JOURNAL OF RARE DISEASES, 2019, 14 (01)
  • [38] Emerging agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?
    Martinez-Peinado, Nieves
    Cortes-Serra, Nuria
    Losada-Galvan, Irene
    Alonso-Vega, Cristina
    Urbina, Julio A.
    Rodriguez, Ana
    VandeBerg, John L.
    Pinazo, Maria-Jesus
    Gascon, Joaquim
    Alonso-Padilla, Julio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (09) : 947 - 959
  • [39] Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease
    Carta, Anna R.
    Simuni, Tanya
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (02) : 219 - 227
  • [40] Development of a first-in-class autologous B cell therapy for the treatment of Fabry disease
    Elliott, Eileen
    Romano, Rosa
    Arenas, Johnny
    Ahene, Ago
    Casanova, Inosencio
    Chang, Robert
    Bengford, David
    Hernandez, Moises
    Li, Grant
    Pios, Ariel
    Rajendiran, Smrithi
    Somebang, Kerri
    Zepecki-France, Kolton
    Brennan, Thomas
    Boyle, Kathleen
    Rakestraw, James A.
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
12345